undamentalytics Newsletter
Sign in

Arvinas, Inc. income statement

In fiscal 2025, Arvinas, Inc. reported revenue of $263m, down 0.3% on the year before, operating income of −$119m (a -45.1% margin) and net income of −$80.8m, or −$1.14 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue81443265413179263263317
Research and development294567108180315380348285239
General and administrative413273862801001659687
Operating income−25−44−52−121−188−263−402−250−119−18
Interest expense00000000——
Income before tax———−115−184−251−364−198−8110
Income tax00000211101
Net income−24−41−70−119−191−283−367−199−819
Diluted EPS−$3.02−$25.45−$2.13−$3.02−$3.82−$5.31−$6.62−$2.77−$1.14$0.14
Diluted shares (average)9m9m33m40m50m53m56m72m71m67m
EBITDA−24−43−50−118−184−257−397−246−116−15

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ARVN vs IOVAADPT vs ARVNARVN vs VCELARVN vs VIR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arvinas, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arvinas, Inc.